Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Phase 2 Unknown
35 enrolled
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Phase 2 Completed
30 enrolled 7 charts
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
Phase 2 Completed
36 enrolled
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Phase 1 Completed
24 enrolled
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Phase 1 Terminated
31 enrolled
IP
Phase 1 Completed
30 enrolled
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Phase 1 Completed
18 enrolled
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Phase 2 Terminated
2 enrolled 7 charts
Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
Phase 2 Terminated
18 enrolled 4 charts
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
Phase 1 Withdrawn
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Phase 2 Completed
23 enrolled
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
Phase 1 Completed
22 enrolled
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
33 enrolled
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Phase 2 Terminated
34 enrolled
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Phase 2 Completed
150 enrolled 11 charts
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
Phase 2 Completed
20 enrolled 8 charts
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Chemotherapy in Treating Patients With Solid Tumors
Phase 1/2 Completed
57 enrolled
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
Phase 2 Terminated
13 enrolled 5 charts
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Phase 2 Completed
82 enrolled
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Completed
30 enrolled
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Phase 2 Completed
31 enrolled
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Phase 1/2 Completed
PRIMOVAR-1
Phase 2 Unknown
100 enrolled